Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

Blood

Volumn 109, Issue 11, 2007, Pages 4599-4606

  Wiestner, Adrian ^a,b   Tehrani, Mahsa ^b   Chiorazzi, Michael ^a   Wright, George ^a   Gibellini, Federica ^b   Nakayama, Kazutaka ^b   Liu, Hui ^b   Rosenwald, Andreas ^c   Muller Hermelink, H Konrad ^c   Ott, German ^c   Chan, Wing C ^d   Greiner, Timothy C ^d   Weisenburger, Dennis D ^d   Vose, Julie ^d   Armitage, James O ^d   Gascoyne, Randy D ^e   Connors, Joseph M ^e   Campo, Elias ^f   Montserrat, Emilio ^f   Bosch, Francesc ^f   Smeland, Erlend B ^g   Kvaloy, Stein ^g   Holte, Harald ^g   Delabie, Jan ^g   Fisher, Richard I ^h   Grogan, Thomas M ^h   Miller, Thomas P ^h   Wilson, Wyndham H ^a   Jaffe, Elaine S ^a   Staudt, Louis M ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^f UNIVERSITY OF BARCELONA   (Spain)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h Southwest Oncology Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; MESSENGER RNA;

3' UNTRANSLATED REGION; ARTICLE; CANCER SURVIVAL; GENE DELETION; GENETIC TRANSCRIPTION; HALF LIFE TIME; HUMAN; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; POINT MUTATION; POLYADENYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA SPLICING; TUMOR CELL LINE;

EID: 34249723211     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-039859     Document Type: Article

References (44)

1. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115-127.
2. Swerdlow SH, Williams ME. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol. 2002;33:7-20.
3. Raffeld M, Jaffe ES. bcl-1, t(11;14), and mantle cell-derived lymphomas. Blood. 1991;78:259-263.
4. Williams ME, Westermann CD, Swerdlow SH. Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus. Blood. 1990;76:1387-1391.
5. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood. 1994;84:2726-2732.
6. Chesi M, Bergsagel PL, Brents LA, Smith CM, Gerhard DS, Kuehl WM. Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood. 1996;88:674-681.
7. 1 cyclins. Cell. 1993;73:1059-1065.
8. Raynaud SD, Bekri S, Leroux D, et al. Expanded range of 11q13 breakpoints with differing patterns of cyclin D1 expression in B-cell malignancies. Genes Chromosomes Cancer. 1993;8:80-87.
9. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene. 2006;25:1620-1628.
10. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005-1011.
11. Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, Arnold A. Cyclin D1 (PRAD1) alternative transcript b: full-length cDNA cloning and expression in breast cancers. Cancer Lett. 1997;113:123-130.
12. Hosokawa Y, Tu T, Tahara H, Smith AP, Arnold A. Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett. 1995;93:165-170.
13. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants: differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003;278:30339-30347.
14. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63:7056-7061.
15. Burd CJ, Petre CE, Morey LM, et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A. 2006;103:2190-2195.
16. Holley SL, Parkes G, Matthias C, et al. Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol. 2001;159:1917-1924.
17. Correa P, Lundgren E, Rastad J, Akerstrom G, Westin G, Carling T. The Neil polymorphism in the cyclin D1 gene and sporadic primary hyperparathyroidism. J Intern Med. 2001;250:516-520.
18. Howe D, Lynas C. The cyclin D1 alternative transcripts [a] and are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica. 2001;86:563-569.
19. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197.
20. Hosokawa Y, Suzuki R, Joh T, et al. A small deletion in the 3′-untranslated region of the cyclin D1/PRAD1/bcl-1 oncogene in a patient with chronic lymphocytic leukemia. Int J Cancer. 1998;76:791-796.
21. Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK, Lichy JH. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem. 2001;47:195-201.
22. Seto M, Yamamoto K, Iida S, et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene. 1992;7:1401-1406.
23. Withers DA, Harvey RC, Faust JB, Melnyk O, Carey K, Meeker TC. Characterization of a candidate bcl-1 gene. Mol Cell Biol. 1991;11:4846-4853.
24. Parrens M, Belaud-Rotureau MA, Fitoussi O, et al. Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features. Histopathology. 2006;48:353-362.
25. Medeiros LJ, Estrov Z, Rassidakis GZ. Z-138 cell line was derived from a patient with blastoid variant mantle cell lymphoma. Leuk Res. 2006;30:497-501.
26. Bevilacqua A, Ceriani MC, Capaccioli S, Nicolin A. Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol. 2003;195:356-372.
27. Guhaniyogi J, Brewer G. Regulation of mRNA stability in mammalian cells. Gene. 2001;265:11-23.
28. Rimokh R, Berger F, Bastard C, et al. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood. 1994;83:3689-3696.
29. Xiong Y, Connolly T, Futcher B, Beach D. Human D-type cyclin. Cell. 1991;65:691-699.
30. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, et al. A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene. 1994;9:1925-1929.
31. Lam L, Pickeral OK, Davis RE, Giltnane J, Sathyamoorthy M, Yu X, et al. Genomic-scale measurement of mRNA turnover using the anticancer drug flavopiridol. Genome Biol. 2001;2:0041.1-0041.11.
32. Chen CY, Gherzi R, Ong SE, et al. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell. 2001;107:451-464.
33. Marderosian M, Sharma A, Funk AP, et al. Tristetraprolin regulates cyclin D1 and c-Myc mRNA stability in response to rapamycin in an Akt-dependent manner via p38 MAPK signaling. Oncogene. 2006; 25:6277-6290.
34. Stoecklin G, Gross B, Ming XF, Moroni C. A novel mechanism of tumor suppression by destabilizing AU-rich growth factor mRNA. Oncogene. 2003;22:3554-3561.
35. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol. 2005;23:5347-5356.
36. Lin S, Wang W, Wilson GM, et al. Down-regulation of cyclin D1 expression by prostaglandin A(2) is mediated by enhanced cyclin D1 mRNA turnover. Mol Cell Biol. 2000;20:7903-7913.
37. Farh KK, Grimson A, Jan C, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005;310:1817-1821.
38. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs down-regulate large numbers of target mRNAs. Nature. 2005;433:769-773.
39. Xie X, Lu J, Kulbokas EJ, et al. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature. 2005;434:338-345.
40. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004;5:396-400.
41. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005;37:495-500.
42. Scotto KW, Yang H, Davide JP, Melera PW. Differential utilization of poly (A) signals between DHFR alleles in CHL cells. Nucleic Acids Res. 1992;20:6597-6604.
43. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 1995;20:465-470.
44. Nair AP, Hahn S, Banholzer R, Hirsch HH, Moroni C. Cyclosporin A inhibits growth of autocrine tumour cell lines by destabilizing interleukin-3 mRNA. Nature. 1994;369:239-242.